Background and Purpose-Our previous studies have shown that bone marrow-derived cells (BMDCs) home to a brain angiogenic focus. The angiogenic response to vascular endothelial growth factor (VEGF) stimulation is reduced in matrix metalloproteinase-9 (MMP-9) knockout mice. We hypothesized that BMDCs contribute to VEGF-induced angiogenesis by supplying MMP-9. Methods-Bone marrow (BM) transplantation was conducted using MMP-9 knockout (MMP-9 KO) or wild-type (WT) mice as both donors and recipients. Adeno-associated viral vectors expressing VEGF or LacZ were injected into the striatum 4 weeks after BM transplantation. Circulating white blood cells (WBCs), microvessel density, number of BMDCs, and MMP-9 activity around the injection site were analyzed. Results-Two weeks after vector injection, circulating WBCs increased in WT mice but not in MMP-9 KO mice. VEGF overexpression increased microvessel density by 38% in WT mice 4 weeks after vector injection (Pϭ0.0001). After transplantation of MMP-9 KO BM to WT mice, microvessel density only increased 18% after VEGF stimulation (Pϭ0.037), with MMP-9 activity reduced to 35% of the level of WT mice (PϽ0.01). There was minimal angiogenic response in MMP-9 KO mice with MMP-9 KO BM (Pϭ0.28). Transplantation of WT BM to MMP-9 KO mice restored brain angiogenic response to 92% of the WT level, ie, a 30% increase of microvessel density with VEGF overexpression (Pϭ0.0006); MMP-9 activity was similar to that in WT mice. Key Words: angiogenesis Ⅲ bone marrow-derived cells Ⅲ brain angiogenesis Ⅲ metalloproteinase-9 Ⅲ vascular endothelial growth factor I ncreasing evidence indicates that bone marrow-derived cells (BMDC) are associated with angiogenesis-related disorders, including tumor 1-3 and brain arteriovenous malformations. 4 BMDC are recognized as a major supplier of matrix metalloproteinases (MMP), 2,5 a family of zinc-dependent endopeptidases responsible for the degradation of extracellular matrix component, for tissue angiogenesis.
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ncreasing evidence indicates that bone marrow-derived cells (BMDC) are associated with angiogenesis-related disorders, including tumor 1-3 and brain arteriovenous malformations. 4 BMDC are recognized as a major supplier of matrix metalloproteinases (MMP), 2,5 a family of zinc-dependent endopeptidases responsible for the degradation of extracellular matrix component, for tissue angiogenesis.
Our previous studies have demonstrated that cerebral angiogenesis can be induced by adeno-associated viral vector (AAV)-mediated vascular endothelial growth factor (VEGF) gene transfer. 6, 7 This angiogenic response to VEGF stimulation was reduced in MMP-9 knockout (KO) mice, 7 suggesting that MMP-9 plays a role in cerebral angiogenesis.
Studies have shown that MMP-9 facilitates mobilization of bone marrow (BM) cells into the circulation 8 and their homing to the tumorangiogenic foci. 3 In this study, we provide direct evidence that BMDC-derived MMP-9 is crucial for VEGF-induced brain angiogenesis.
Our primary motivation for undertaking this study of the association of BM-derived MMP-9 and angiogenesis is in the context of various brain vascular malformations, especially brain arteriovenous malformations. The other neurological diseases, including tumor, are secondary areas of potential relevance.
Materials and Methods

Experimental Design
The experimental design and groups are shown in Figure 1 and the Table. All experimental procedures for using laboratory animals were approved by the Institutional Animal Care and Use Committee, University of California, San Francisco. Adult male mice at age 8 to 10 weeks in the C57BL/6 background carrying homozygous null mutations of the MMP-9 gene 9 (a gift from Dr. Zena Werb, Depertment of Anatomy, University of California, San Francisco, CA) and their wild-type (WT) littermates were used as BM donors and recipients in all the experiments. For Methods and Statistical Analysis, please see Supplemental Methods (available online at http://stroke.ahajournals.org).
Results
MMP-9 Facilitates the Mobilization of BM Cells Into the Circulation
WTϩWT BM and MMP-9 KOϩKO BM mice were used to explore the effects of MMP-9 on BM cell mobilization in response to VEGF stimulation. The mice in these 2 groups had a similar baseline of total circulating white blood cells (WBC). Total WBC increased to 160% of baseline (Pϭ0.0015) in WTϩWT BM mice 14 days after intrabrain injection of AAV-VEGF, decreased thereafter, and then returned to baseline on day 25 (Figure 2A ). The total WBC increased slightly on day 8 only (135% of baseline; Pϭ0.08) in MMP-9 KOϩKO BM mice. Thus, VEGF could not induce a significant increase in total WBC in KOϩKO BM mice.
Both neutrophils and lymphocytes peaked on day 14 and returned to baseline on day 25 in VEGF-treated WTϩWT BM mice ( Figure 2B , C). They were the major cell types responsible for the increase of total WBC at this time point. These cells did not increase in KOϩKO BM mice. Monocytes increased in WTϩWT BM mice but not in KOϩKO BM mice on day 14 after AAV-VEGF and AAV-LacZ vector injection ( Figure 2D ). These data suggest that MMP-9 facilitates BM cell mobilization in response to VEGF stimulation.
VEGF Treatment Induces MMP-9 Expression in BM Cells
We then determined whether the increased mobilization of BM cells in VEGF-treated WTϩWT BM mice was attributable to the upregulation of MMP-9 in the BM cells. We analyzed MMP-9 expression in BM tissue collected from WTϩWT BM and MMP-9 KOϩKO BM mice. Very few MMP-9-positive cells were detected in the BM of LacZ-treated WTϩWT BM mice (data not shown). MMP-9-positive signals were detected in BM sections of VEGF-treated WTϩWT BM mice ( Figure 2E , parts c and d), but not in KOϩKO BM mice ( Figure 2E , parts a and b). These results suggest that VEGF upregulated MMP-9 expression in BM cells.
MMP-9 Promotes the Recruitment of BMDC to the Angiogenic Foci
We then explored the role of MMP-9 in the recruitment of BMDC from the circulation to the angiogenic foci in the mouse brain. The brain sections were stained with an antibody specific to CD45, a common leukocyte marker. CD45 
Transplantation of WT BM Rescued the Impaired Brain Angiogenesis of MMP-9 KO Mice
Microvessel density increased 38% in the brain of VEGFtreated WTϩWT BM mice (Figure 4C , D; 318Ϯ44 vs 230Ϯ16, VEGF vs LacZ; Pϭ0.0001) and 18% in VEGFtreated WTϩKO BM mice ( Figure 4C ; 248Ϯ13 vs 210Ϯ34, VEGF vs LacZ; Pϭ0.037). VEGF did not induce significant angiogenesis in the brain of KOϩKO BM mice (231Ϯ31 vs 211Ϯ40, VEGF vs LacZ; Pϭ0.28). Transplantation of WT BM partially rescued the impaired angiogenic response in MMP-9 KO mice, indicated by an increase of microvessel density to 30% in the brain of AAV-VEGF-injected mice compared to that of AAV-LacZ-injected mice ( Figure 4C ; 278Ϯ19 vs 213Ϯ29, VEGF vs LacZ; Pϭ0.0006). These results suggest that BMDC homing is crucial for VEGFinduced brain focal angiogenesis.
We then used antibodies specific to CD31 and cell proliferating marker BrdU to show the proliferating endothelial cells. The numbers of BrdU/CD31-double-positive cells in each group paralleled the data for microvessel density. There were more double-positive cells in KOϩWT BM compared to KOϩKO BM mice and fewer double-positive cells in WTϩKO BM compared to WTϩWT BM mice ( Figure 4E ).
We also analyzed the correlation of microvessel density with injected vectors, recipient genotypes, and donor BM genotypes using 3-way ANOVA. We observed that injection of AAV-VEGF increased microvessel density (Pϭ0.0001; AAV-VEGF vs AAV-LacZ). VEGF was more effective in WTϩWT BM mice compared to MMP-9 KO ϩKO BM mice (Pϭ0.0642) and WT mice with MMP-9 KO BM (Pϭ0.0037) genotypes. Linear regression revealed that both recipient (Pϭ0.022) and donor BM (Pϭ0.002) genotypes influenced the microvessel density in the VEGF-treated brain ( Figure 4C ). 
BMDC Are Important Sources of MMP-9 in the Brain Angiogenic Foci
To investigate whether BMDC are important sources of MMP-9 in VEGF-induced angiogenic foci in the mouse brain, we examined the level of MMP-9 activity in the VEGF-treated brain using zymography. A higher level of MMP-9 was detected in VEGF-treated WTϩWT BM mice (3.7Ϯ2.2) than in MMP-9 KOϩKO BM mice (1.0Ϯ0.1; Figure 5 ; PϽ0.01). The MMP-9 level was significantly reduced in WTϩKO BM mice (1.3Ϯ0.3) but was greatly increased in KO mice that underwent transplantation with WT BM (3.8Ϯ1.1; Figure 5 ; PϽ0.01). These results suggest that BMDC provided a significant amount of MMP-9 to the VEGF-induced brain angiogenic foci.
Discussion
This study is the first to our knowledge to show that after VEGF administration in the adult mouse brain: (1) circulating WBC increased in WTϩWT BM mice (accompanied by MMP-9 expression in the BM) but not in MMP-9 KOϩKO BM mice, suggesting that MMP-9 activation facilitates mobilization; (2) numerous BMDC (CD45 ϩ cells) were observed in the brain of WTϩWT BM mice and few were observed in the brain of KOϩKO BM mice, suggesting that MMP-9 promotes the recruitment of BMDC to VEGFinduced angiogenic foci; and (3) focal brain angiogenesis decreased in WT mice that underwent transplantation with KO BM, accompanied by a reduced level of brain MMP-9, whereas transplantation of WT BM partially rescued the impaired angiogenic response of MMP-9 KO mice, with an increased level of brain MMP-9. Taken together, our results demonstrate that BM-derived MMP-9 facilitates the mobilization of BM cells into the circulation and their homing to the angiogenic foci in response to VEGF stimulation. BMDC contribute to angiogenesis by supplying MMP-9.
MMP-9 Is Crucial for VEGF-Induced BM Cell Mobilization
Stem cells are quiescent in the BM niche, but they are mobilized to the peripheral blood in response to specific signals. Singledose intravenous injection of Adenoviral vector (Ad)-VEGF increases circulating WBC in WT mice, which is MMP-9-dependent and is associated with an elevation of VEGF plasma level. 8 Our results showed that intrabrain injection of AAV-VEGF increased circulating WBC to 160% of baseline in WTϩWT BM mice. This effect was not observed in MMP-9 KOϩKO BM mice ( Figure 2A ). The number of circulating WBC peaked on day 14, likely the peak of plasma VEGF; Heissig et al 8 showed in their article that the peak of the mature WBC in circulation correlated with the peak of plasma VEGF level. Further studies are needed to prove this in our model. Activated MMP-9 within the BM liberates soluble kitligand, thereby mobilizing BM cells into the circulation. 8, 10 We showed that injection of AAV-VEGF into the mouse brain increased MMP-9 expression in BM cells ( Figure 2E ), resulting in increased mobilization of BM cells, as demonstrated by increased circulating WBC. Although soluble kit-ligand released by induced MMP-9 in BM cells seems to be the key factor in the process, further studies to investigate whether exogenous soluble kit-ligand rescues impaired BM mobilization in MMP-9 KO mice may provide more evidence.
BMDC Contribute to VEGF-Induced Focal Brain Angiogenesis by Supplying MMP-9
We have previously studied whether BMDC (tracked by green fluorescent protein expression after transplantation of BM cells harvested from green fluorescent protein mice to WT mice) can be recruited into AAV-VEGF-induced angiogenic foci, and whether they incorporate into the neovasculature. 7 We demonstrated that MMP-9 activity is necessary for the VEGF-induced focal angiogenesis by injecting AAV-VEGF into the brain of MMP-9 KO mice. 7 However, we have no direct evidence to show that BMDC contribute to MMP-9 in the VEGF-induced angiogenic foci.
In the current study, we used a BM transplantation mouse model to test our hypothesis that MMP-9 derived from BMDC is crucial for VEGF-induced brain angiogenesis. We found that transplanting MMP-9 KO BM to WT mice resulted in a reduction of their brain angiogenic response to VEGF stimulation, whereas transplanting WT BM to MMP-9 KO mice partially rescued their brain angiogenic response. Thus, this study provides solid evidence that BMDC-derived MMP-9 contributes to VEGF-induced brain focal angiogenesis. In addition, we demonstrate that MMP-9 facilitates the mobilization of BM cells into the circulation, which subsequently may facilitate their recruitment into the mouse brain angiogenic foci.
To what extent BMDC incorporate into the neovasculature remains controversial. Despite the fact that only small fractions of circulation cells are monocytes, we found that most of BMDC homing to VEGF-stimulated brain angiogenic focus are CD45 ϩ (94%) and CD68 ϩ (71%) cells. 7 Others also have found that BMDC infiltrating into the brain give rise primarily to microglia. [11] [12] [13] [14] Studies including ours have shown that BMDC are recruited to the angiogenic foci but are rarely incorporated into the vessel structure, 1, 7, 15, 16 suggesting a paracrine angiogenic role for BMDC.
In this study, transplantation of BM cells from MMP-9 KO mice into WT recipient mice, and vice versa, was conducted to study the effects of BM-derived MMP-9 on VEGF-induced focal brain angiogenesis. Brain angiogenesis indicated by microvessel density decreased in VEGF-treated WTϩKO BM mice compared to WTϩWT BM mice, accompanied by a decrease in MMP-9 level to 35% of that in WTϩWT BM mice; the impaired angiogenesis in MMP-9 KO mice was partially rescued by transplantation of WT BM. A nearnormal level of MMP-9 activity was also detected in the brain of MMP-9 KO mice that underwent transplantation with WT BM. These results suggest that BM-derived MMP-9 is crucial for cerebral angiogenesis, and that BMDC are an important source of MMP-9 in the VEGF-induced angiogenic foci. MMP-9 provided by BMDC promotes local angiogenesis by degrading the extracellular matrix, resulting in capillary branching. It also cleaves membrane-bound cytokines 17 such as VEGF, which, in turn, promotes angiogenesis. 18 Moreover, BMDC themselves express VEGF and other angiogenic factors. 19 MMP-9, the major player, delivered by recruited BMDC along with other BMDC-derived proangiogenic factors modulates proliferation of local endothelial cells.
Interestingly, microvessel density slightly increased in the brain of VEGF-treated WT mice that underwent transplantation with MMP-9 KO BM mice, and transplantation of WT BM partially rescued the impaired angiogenesis in MMP-9 KO mice. Our results suggest that although BMDC are the major participant in VEGF-induced focal brain angiogenesis, resident non-BM cells of the recipient brain may compensate partly for the lack of BMDC-derived MMP-9. The statistical analysis confirms that both the somatic genotype and BM genotype influenced the microvessel density in the VEGFtreated brain.
A limitation of our study is that we did not clarify the contribution of various resident cell types in the target brain tissue. We did observe a weak band of MMP-9 in the brain of WT mice that underwent transplantation with MMP-9 KO BM ( Figure 5A ), which is probably derived from other resident cells in the brain such as neurons, astrocytes, or endothelia. Another limitation of our study is that we did not clarify how BM and the brain communicate, although this phenomenon has been observed by other investigators. 20 The possibility exists that the signal from the brain to the BM derives from circulating VEGF. Heissig et al 8 have shown that plasma VEGF level increased after Ad-VEGF injection (intravenous). We believe that an increase of plasma VEGF was present in our mice, which will be addressed in our future studies.
The important point that our study makes is that a biologically significant fraction of MMP-9 activity arrives at an angiogenic focus from the extracranial BM site. Not only is this important for understanding the precise mechanisms and procedural considerations for a focal angiogenic response but also it opens up a potential line of inquiry to target this blood-borne source of protease activity for eventual new therapeutic approaches for angiogenic-related neurological disorders.
Conclusion
In this study, we showed that BM-derived MMP-9 plays a key role in VEGF-induced brain angiogenesis, including BM cell mobilization and BMDC recruitment to the angiogenic foci. BMDC contribute to focal angiogenesis by supplying MMP-9. Our study suggests that modifying MMP-9 activity of BMDC may be a therapeutic strategy for the treatment of angiogenic-related disorders, such as brain arteriovenous malformations and brain tumor.
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Supplemental Methods
BM Transplantation
BM transplantation was performed as previously described. 1 BM cells ( 2X10 6 ) from 8-week-old donor mice were injected into lethally irradiated (9.7 Gy from GC3000 Irradiator, MDS-Nordion, Ottawa, Canada) recipient mice via the tail vein. To facilitate the determination of the reconstitute rate, we transplanted GFP positive BM cells to a group of WT mice in parallel. Circulating blood was collected 4 weeks after BM transplantation. Flow cytometric analysis showed that 90-93% of nucleated cells in the recipient mice expressed GFP, indicating a high reconstitute rate of recipient BM by donor BM.
WBC Quantification and Sample Collection
Four weeks after the BM transplantation, recipient mice were anesthetized using ketamine/xylazine (100/10 mg/kg body weight). Two µl of viral suspension containing 2 X 10 9 genome copies of AAV-VEGF or AAV-LacZ were injected into the right basal ganglia at a rate of 0.2 µl per minute.
Circulating blood was collected from the retro-orbital plexus on days 0, 5, 8, 11, 14, 17, 21, and 25 after gene transfer, and WBCs were quantified with a HEMAVET (Model 950, DREW Scientific Inc, Oxford, CT). All blood samples were taken at the same time of the day. A total of 50 µl of blood was collected from each mouse at each time point for the measurement. Mice were sacrificed 4 weeks after vector injection, and the brain and femur were harvested. Before the animals were euthanized, BrdU (100 mg per mouse) was injected intraperitoneally to the mice daily for 5 consecutive days.
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AAV Vector Injection
Immunohistochemistry
Twenty µm thick brain coronal cryostat sections, prepared from 1 mm rostral to 1 mm caudal of the injection site, were used for immunohistochemical staining. Antibodies specific to CD45 (BD Biosciences, San Jose, CA), BrdU (Sigma-Aldrich, St. Louis, MO), CD31 (BD Biosciences), and MMP-9 (a gift from Dr. Robert Senior of Washington University, St. Louis, MO) were used.
Quantification of Microvessel Density
3
We have established a relatively simple and reliable method to quantify the number of microvessels in a given brain region using lectin (fluoresceinlycopersicin esculentum lectin, Vector Lab)-stained sections, referred to as "microvessel density." 3 The microvessel density is heterogeneous in the cerebral cortex by both region and cortical layer. Thus, we injected the viral vector into the basal ganglia and analyzed the microvessel density in the pictures taken from similar regions in all the animals. Briefly, the injection needle was inserted in a burr hole drilled into the pericranium 1 mm lateral to the sagittal suture, 1 mm posterior to the coronal suture, and 3 mm under the cortex surface. We took 2 sections, 1 mm rostral and 1 mm caudal of the injection site, for the microvessel density analysis. Sections were stained with lectin (2 µg/ml, Vector Laboratories). Three images were taken from each lectin-stained section (to the right and left of and below the injection site) under 10X objective lens ( Figure 4A & B) . Microvessel numbers in each picture were counted using NIH Image 1.63 software. Two investigators without knowledge of treatment conditions assessed vessel counts separately. Microvessel density for each animal was calculated as the mean of the microvessel counts obtained from the six pictures. The microvessel density analyzed in the sections selected as described above should be comparable.
Gelatin Zymogram for MMP-9 Activity Detection
Equal amounts of protein prepared from brain tissues were loaded onto a Novex 10% gelatin gel (Invitrogen). Gel was subjected to electrophoresis and stained with Coomassie Blue R-250 (Bio-Rad Laboratories, Hercules, CA). The densities of MMP-9 bands were quantified using NIH Image 1.63 software. The data are presented as the densities of each sample relative to the mean density of MMP-9 KO+KO BM group.
Statistical Analysis
Data are expressed as mean±SD. The influence of VEGF on the WBC counts, microvessel density, and MMP-9 activity was analyzed using one-way ANOVA followed by Fisher's protected least significant difference (PLSD) test. A probability (P) value <0.05 was considered statistically significant.
We also analyzed the correlation of microvessel densities with recipient genotype (MMP-9 KO or WT), donor BM genotype (MMP-9 KO or WT) and injection type (AAV-VEGF or AAV-LacZ) using a three-way ANOVA analysis. To estimate the effect magnitude, we performed linear regression assay.
